Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000647996 | SCV000769806 | pathogenic | Qualitative or quantitative defects of dysferlin | 2023-10-03 | criteria provided, single submitter | clinical testing | This sequence change affects a donor splice site in intron 46 of the DYSF gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in DYSF are known to be pathogenic (PMID: 17698709, 20301480). This variant is present in population databases (rs773386253, gnomAD 0.0009%). Disruption of this splice site has been observed in individuals with limb girdle muscular dystrophy type 2B (PMID: 16100712). ClinVar contains an entry for this variant (Variation ID: 538631). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. |
Counsyl | RCV000669143 | SCV000793860 | pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2B | 2017-09-01 | criteria provided, single submitter | clinical testing | |
Eurofins Ntd Llc |
RCV000733066 | SCV000861085 | pathogenic | not provided | 2018-05-08 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002499105 | SCV002813224 | likely pathogenic | Miyoshi muscular dystrophy 1; Autosomal recessive limb-girdle muscular dystrophy type 2B; Distal myopathy with anterior tibial onset | 2021-08-20 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV000669143 | SCV002080314 | pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2B | 2021-10-19 | no assertion criteria provided | clinical testing |